



Antiviral T and B Cell Immunity

Guest Editors:

Dr. Constantinos Petrovas

Dr. Ashish Arunkumar Sharma

Dr. Susan Pereira Ribeiro

Deadline for manuscript
submissions:

15 September 2024

Message from the Guest Editors

The aim of this Special Issue is to present the latest developments regarding the dynamics of human antiviral immune responses and how this knowledge could fuel the further development of novel vaccine strategies. The comprehensive understanding of relevant immune cell phenotypes and their function, molecular programming, and spatial positioning at the tissue level will significantly improve our knowledge for their development and will potentially provide novel molecules/pathways that could be used for the discovery of novel strategies aiming towards *in vivo* generation/manipulation and the elimination of viruses like HIV.

Research areas may include, but not limited to, the following:

1. Vaccine-induced antiviral responses: phenotypes, molecular programming, tissue dynamics.
2. Natural infection-induced antiviral responses, especially ones focused on secondary lymphoid organs and how that could inform vaccine development.
3. Novel technologies for the investigation of antiviral responses/immune dynamics, with emphasis on their spatial positioning.
4. Studies on relevant animal models, NHP, and humanized mice.
5. Comparative studies of immune dynamics between different diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com